Floatz logo

Hydroxychloroquine

Chemotherapy-Induced Neuropathy

University of ArizonaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Chemotherapy-Induced Neuropathy cohort.

Asset / SponsorPhaseRating
Pregabalin
University of Rochester
Phase 4BB
Omeprazole
Aya Mohamed Sadek Elsaid
Phase 3BB
LIDOCAINE
Hospital Ambroise Paré Paris
Phase 2BB
Mecobalamin
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2/3B
Vitamin B6
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2/3B

View all 44 →

Same molecule, other indications

Hydroxychloroquine is also rated in:

cutaneous melanomaDormant
B
Indicative ·
61 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
pancreatic adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →